

PMR Public Report

| | | | | | | | | | |
|---|---|---|-----------------------------|------------------------|---------------------|------------------------|----------------------|-------------|--------------------|
| Operation Number | PR-L1167 | Chief of Operations Validation Date | 04/07/22 | | | | | | |
| Year- PMR Cycle | Second period Jan-Dec 2021 | Division Chief Validation Date | 04/11/22 | | | | | | |
| Last Update | 03/30/22 | Country Representative Validation Date | 05/09/22 | | | | | | |
| PMR Validation Stage | Validated by Representative | | | | | | | | |
| Basic Data | | | | | | | | | |
| Operation Profile | | | | | | | | | |
| Operation Name | Program to Strengthen Integrated and Comprehensive Health Services Networks based on Primary Health Care | Loan Number | 4872/OC-PR | | | | | | |
| Executing Agency | MINISTERIO DE SALUD PUBLICA Y BIENESTAR SOCIAL | Sector/Subsector | HEALTH-PRIMARY HEALTH CARE | | | | | | |
| Team Leader | OCHOA, FRANCISCO JOSE | Overall Stage | Signed/Pending Ratification | | | | | | |
| Operation Type | Loan Operation | Country | Paraguay | | | | | | |
| Lending Instrument | Investment Loan | Convergence related Operation(s) | | | | | | | |
| Borrower | REPUBLICA DE PARAGUAY | | | | | | | | |
| Environmental and Social Safeguards | | | | | | | | | |
| Impacts Category | B | Was/Were the objective(s) of this operation reformulated? | NO | | | | | | |
| Safeguard Performance Rating | Satisfactory | Date of approval | | | | | | | |
| Safeguard Performance Rating - Rationale | El programa ha sido aprobado por el Directorio en cumplimiento con las políticas de salvaguardias ambientales y sociales, no cuenta aún con elegibilidad y no ha empezado ejecución. En la fase de preparación se elaboraron los siguientes documentos: Análisis Ambiental y Social/Plan de Gestión Ambiental y Social; Análisis Socio cultural; Plan e informe de Consultas para las obras de la muestra, y un MGAS para el programa que regirá a los proyectos futuros. | | | | | | | | |
| Financial Data | | | | | | | | | |
| | Total Cost and Source | | | | | Available Funds (US\$) | | | |
| Operations | Original IDB | Current IDB | Local Counterpart | Co-Financing / Country | Total Original Cost | Current IDB | Disb. Amount to Date | % Disbursed | Undisbursed Amount |
| PR-L1167 | 45,000,000 | 45,000,000 | 0 | 0 | 45,000,000 | 45,000,000 | - | 0.00% | 45,000,000 |
| Aggregated | 45,000,000 | 45,000,000 | 0 | 0 | 45,000,000 | 45,000,000 | - | 0.00% | 45,000,000 |
| Expense Categories by Loan Contract (cumulative values) | | | | | | | | | |

No Data Available

Please note that inactive indicators and outputs are not displayed; totals in the actual cost table may not match the sum of the cost of the outputs displayed, due to the cost of inactive outputs.

RESULTS MATRIX

General Development Objectives

General Development Objectives Nbr. 1: Contribuir a la mejora de las condiciones de salud de la población más vulnerable de Paraguay, a través del fortalecimiento de las RIISS basadas en Atención Primaria de Salud (APS).

Observation:

| Indicator | | Unit of Measure | Baseline | Baseline Year | Expected Year of Achievement | EOP 0 | |
|-----------|-----------------------------------|------------------------|----------|---------------|------------------------------|-------|----|
| 1.0 | Razón de mortalidad materna (RMM) | /100.000 nacidos vivos | 67.3 | 2017 | 2025 | P | 52 |
| | | | | | | A | - |
| Details | | | | | | | |

Means of Verification: MSPyBS/Subsistema de Información de Estadísticas Vitales (SSIEV). Indicadores Básicos de Salud (IBS)/Indicadores de Mortalidad (INDIMOR)

Observations: Cálculo: RMM = N° de muertes maternas en determinado local y período / N° de nacidos vivos en determinado local y período *100.000

The General Development Objective indicator target is expected to be observed by the operation's "Fully Justified" date in Convergence (CO): No

| Pro-Gender | No | Pro-Ethnicity | No | CRF indicator | | | | | |
|------------|-----------------------------|---------------|----|----------------------|----------|---------------|------------------------------|-------|-----|
| | | | | | | | | | |
| Indicator | | | | Unit of Measure | Baseline | Baseline Year | Expected Year of Achievement | EOP 0 | |
| 1.2 | Tasa de Mortalidad neonatal | | | /1.000 nacidos vivos | 9 | 2017 | 2025 | P | 7.6 |
| | | | | | | | | A | - |
| Details | | | | | | | | | |

Means of Verification: MSPyBS/Subsistema de Información de Estadísticas Vitales (SSIEV). Indicadores Básicos de Salud (IBS)/Indicadores de Mortalidad (INDIMOR)

Observations: Cálculo: TMN = N° de óbitos de niños de menos de 28 días de edad en determinada región / N° de nacidos vivos registrados en el mismo local y período)*1.000

The General Development Objective indicator target is expected to be observed by the operation's "Fully Justified" date in Convergence (CO): No

| Pro-Gender | No | Pro-Ethnicity | No | CRF indicator | | | | | |
|------------|---|---------------|----|-----------------|----------|---------------|------------------------------|-------|----|
| | | | | | | | | | |
| Indicator | | | | Unit of Measure | Baseline | Baseline Year | Expected Year of Achievement | EOP 0 | |
| 1.3 | Tasa de mortalidad prematura por Diabetes Mellitus (DM) - MUJERES | | | /100.000 hab | 44 | 2017 | 2025 | P | 42 |
| | | | | | | | | A | - |
| Details | | | | | | | | | |

Means of Verification: MSPyBS/Subsistema de Información de Estadísticas Vitales (SSIEV). Indicadores Básicos de Salud (IBS)/Indicadores de Mortalidad (INDIMOR)

Observations: Cálculo: TM por DM= N° de óbitos por DM (E10-E14) en la población femenina de 30 a 70 años de edad en determinado local y período /población femenina de 30 a 70 años en el mismo local y período)*100.000 Seguimiento de Género, pro-género

The General Development Objective indicator target is expected to be observed by the operation's "Fully Justified" date in Convergence (CO): No

| Pro-Gender | Yes | Pro-Ethnicity | No | CRF indicator | | | | | |
|------------|---|---------------|----|-----------------|----------|---------------|------------------------------|-------|------|
| | | | | | | | | | |
| Indicator | | | | Unit of Measure | Baseline | Baseline Year | Expected Year of Achievement | EOP 0 | |
| 1.4 | Tasa de mortalidad prematura por Diabetes Mellitus (DM) - Hombres | | | /100.000 hab | 32.9 | 2017 | 2025 | P | 30.9 |
| | | | | | | | | A | - |
| Details | | | | | | | | | |

Means of Verification: MSPyBS/Subsistema de Información de Estadísticas Vitales (SSIEV). Indicadores Básicos de Salud (IBS)/Indicadores de Mortalidad (INDIMOR)

Observations: Cálculo: TM por DM= N° de óbitos por DM (E10-E14) en la población masculina de 30 a 70 años de edad en determinado local y período /población masculina de 30 a 70 años en el mismo local y período)*100.000 Seguimiento de Género, pro-género

The General Development Objective indicator target is expected to be observed by the operation's "Fully Justified" date in Convergence (CO): No

| | | | | | | | | | |
|------------|---|---------------|----|-----------------|----------|---------------|------------------------------|-------|----|
| Pro-Gender | Yes | Pro-Ethnicity | No | CRF indicator | | | | | |
| | | | | | | | | | |
| Indicator | | | | Unit of Measure | Baseline | Baseline Year | Expected Year of Achievement | EOP 0 | |
| 1.5 | Tasa de mortalidad prematura por enfermedades cerebrovasculares – Mujeres | | | /100.000 hab | 24.1 | 2017 | 2025 | P | 22 |
| | | | | | | | | A | - |
| Details | | | | | | | | | |

Means of Verification: MSPyBS/Subsistema de Información de Estadísticas Vitales (SSIEV).

Observations: Cálculo: TM por DIC= N° de óbitos por ECV (I60-I69) en la población femenina en determinado local y período /población femenina en el mismo local y período) *100.000 Seguimiento de Género, pro-género

The General Development Objective indicator target is expected to be observed by the operation's "Fully Justified" date in Convergence (CO): No

| | | | | | | | | | |
|------------|---|---------------|----|-----------------|----------|---------------|------------------------------|-------|------|
| Pro-Gender | Yes | Pro-Ethnicity | No | CRF indicator | | | | | |
| | | | | | | | | | |
| Indicator | | | | Unit of Measure | Baseline | Baseline Year | Expected Year of Achievement | EOP 0 | |
| 1.6 | Tasa de mortalidad prematura por enfermedades cerebrovasculares - Hombres | | | /100.000 hab | 33.9 | 2017 | 2025 | P | 31.9 |
| | | | | | | | | A | - |
| Details | | | | | | | | | |

Means of Verification: MSPyBS/Subsistema de Información de Estadísticas Vitales (SSIEV).

Observations: Cálculo: TM por DIC= N° de óbitos por ECV (I60-I69) en la población masculina en determinado local y período /población masculina en el mismo local y período) *100.000 Seguimiento de Género, pro-género

The General Development Objective indicator target is expected to be observed by the operation's "Fully Justified" date in Convergence (CO): No

| | | | | | | | | | |
|------------|--|---------------|----|-----------------|----------|---------------|------------------------------|-------|----|
| Pro-Gender | Yes | Pro-Ethnicity | No | CRF indicator | | | | | |
| | | | | | | | | | |
| Indicator | | | | Unit of Measure | Baseline | Baseline Year | Expected Year of Achievement | EOP 0 | |
| 1.7 | Tasa de mortalidad por cardiopatía isquémica - Mujeres | | | /100.000 hab | 29 | 2017 | 2025 | P | 27 |
| | | | | | | | | A | - |
| Details | | | | | | | | | |

Means of Verification: MSPyBS/Subsistema de Información de Estadísticas Vitales (SSIEV).

Observations: Cálculo: TM por DIC= N° de óbitos por enfermedades cardíacas isquémicas (I20 –I25) en la población femenina en determinado local y período /población femenina en el mismo local y período)*100.000 Seguimiento de Género, pro-género

The General Development Objective indicator target is expected to be observed by the operation's "Fully Justified" date in Convergence (CO): No

| | | | | | | | | | |
|------------|--|---------------|----|-----------------|----------|---------------|------------------------------|-------|------|
| Pro-Gender | Yes | Pro-Ethnicity | No | CRF indicator | | | | | |
| | | | | | | | | | |
| Indicator | | | | Unit of Measure | Baseline | Baseline Year | Expected Year of Achievement | EOP 0 | |
| 1.8 | Tasa de mortalidad por cardiopatía isquémica - Hombres | | | /100.000 hab | 56.9 | 2017 | 2025 | P | 54.9 |
| | | | | | | | | A | - |
| Details | | | | | | | | | |

Means of Verification: MSPyBS/Subsistema de Información de Estadísticas Vitales (SSIEV).

Observations: Cálculo: TM por DIC= N° de óbitos por enfermedades cardíacas isquémicas (I20 –I25) en la población masculina en determinado local y período /población masculina en el mismo local y período)*100.000 Seguimiento de Género, pro-género

The General Development Objective indicator target is expected to be observed by the operation's "Fully Justified" date in Convergence (CO): No

| | | | | | |
|------------|-----|---------------|----|---------------|--|
| Pro-Gender | Yes | Pro-Ethnicity | No | CRF indicator | |
| | | | | | |

RESULTS MATRIX

Specific Development Objectives

Specific Development Objectives Nbr. 1: Nivel de RS a ser intervenidas (promedio entre Concepción, San Pedro, Caazapá, Alto Paraná)

Observation:

| Indicator | | Unit of Measure | Baseline | Baseline Year | EOP 0 | |
|-----------|--|--------------------|----------|---------------|-------|----|
| 1.0 | Tasa de hospitalización por Diabetes Mellitus y sus complicaciones | /10.000 habitantes | 19.6 | 2017 | P | 18 |
| | | | | | A | - |

Details

Means of Verification: Sistema de Egreso Hospitalarios

Observations: Cálculo: N° internaciones por DM en los establecimientos de las 4 Regiones y período /población en el mismo local y período (año) *10.000

Evaluation Methodology: -

| | | | | | | |
|------------|-----|---------------|----|---------------|--|--|
| Pro-Gender | Yes | Pro-Ethnicity | No | CRF indicator | | |
| | | | | | | |

| Indicator | | Unit of Measure | Baseline | Baseline Year | EOP 0 | |
|-----------|--|-----------------|----------|---------------|-------|------|
| 1.2 | Porcentaje de Hospitalizaciones evitables en mujeres | % | 11.2 | 2017 | P | 10.8 |
| | | | | | A | - |

Details

Means of Verification: Sistema de Egreso Hospitalarios

Observations: Cálculo: N° internaciones por hospitalizaciones prevenibles mujeres / Número total de hospitalizaciones mujeres *1000

Evaluation Methodology: -

| | | | | | | |
|------------|-----|---------------|----|---------------|--|--|
| Pro-Gender | Yes | Pro-Ethnicity | No | CRF indicator | | |
| | | | | | | |

| Indicator | | Unit of Measure | Baseline | Baseline Year | EOP 0 | |
|-----------|--|-----------------|----------|---------------|-------|------|
| 1.3 | Porcentaje de Hospitalizaciones evitables en hombres | % | 16.1 | 2017 | P | 16.1 |
| | | | | | A | - |

Details

Means of Verification: Sistema de Egreso Hospitalarios

Observations: Cálculo: N° internaciones por hospitalizaciones prevenibles hombres / Número total de hospitalizaciones hombres*1000

Evaluation Methodology: -

| | | | | | | |
|------------|-----|---------------|----|---------------|--|--|
| Pro-Gender | Yes | Pro-Ethnicity | No | CRF indicator | | |
| | | | | | | |

| Indicator | | Unit of Measure | Baseline | Baseline Year | EOP 0 | |
|-----------|--|-----------------|----------|---------------|-------|----|
| 1.4 | Controles prenatales iniciados antes de la semana veinte de embarazo | % | 5 | 2017 | P | 40 |
| | | | | | A | - |

Details

Means of Verification: Sistema de Información SAA/ SIG

Observations: Cálculo: Número de Controles Prenatales casos nuevos antes de las 20 semanas / Total de Controles Prenatales Casos Nuevos *100.

Evaluation Methodology: -

| | | | | | | |
|------------|----|---------------|----|---------------|--|--|
| Pro-Gender | No | Pro-Ethnicity | No | CRF indicator | | |
| | | | | | | |

| Indicator | | Unit of Measure | Baseline | Baseline Year | EOP 0 | |
|-----------|--|-----------------|----------|---------------|-------|---------|
| 1.5 | Beneficiarios que reciben servicios de salud | Personas | 647403 | 2017 | P | 864,403 |
| | | | | | A | - |

Details

Means of Verification: MSPBS Dirección de APS Informe Mensual de APS/censo de las USF

Observations: Actualmente las Regiones Intervenidas cubren un total de 647.403 personas censadas 39% con relación a las 1.667.819 personas según la DGEEC. con la Instalación de 62 nuevas USF se cubrirá a 217.000 aumentando un 13% la cobertura, alcanzando así un 52% de cobertura de personas. Este es un indicador corporativo, previsto en la GN-2727-6.

Evaluation Methodology: -

| | | | | | |
|------------|----|---------------|----|---------------|--|
| Pro-Gender | No | Pro-Ethnicity | No | CRF indicator | |
| | | | | | |

| Indicator | | Unit of Measure | Baseline | Baseline Year | EOP 0 | |
|-----------|--|-----------------|----------|---------------|-------|----|
| 1.6 | Mujeres de 25 a 64 años que realizan control de citología cervicovaginal | % | 23 | 2017 | P | 35 |
| | | | | | A | - |

Details

Means of Verification: Sistema Experto control de cáncer de cuello uterino e informes mensuales.

Observations: Calculo: Numero de citologías realizadas en los últimos doce meses/ Número total de mujeres de la población meta de (166.726)

Evaluation Methodology: -

| | | | | | |
|------------|-----|---------------|----|---------------|--|
| Pro-Gender | Yes | Pro-Ethnicity | No | CRF indicator | |
| | | | | | |

RESULTS MATRIX

OUTPUTS: ANNUAL PHYSICAL AND FINANCIAL PROGRESS

Component Nbr. 1 Fortalecimiento del modelo de atención de RIISS, basado en APS

| | | | | PHYSICAL PROGRESS | | FINANCIAL PROGRESS | |
|------|--|-----------------|-------|-------------------|-------|--------------------|--------------|
| | Output | Unit of Measure | | 2021 | EOP 0 | 2021 | EOP 0 |
| 1.01 | USF intervenidas | USF | P | - | 129 | 297,630.43 | 22,642,629.9 |
| | | | P (a) | - | 129 | - | 22,642,629.9 |
| | | | A | - | - | - | - |
| 1.02 | Hospitales readecuados | Hospitales | P | - | 4 | - | 3,029,393.03 |
| | | | P (a) | - | 4 | - | 3,029,393.03 |
| | | | A | - | - | - | - |
| 1.03 | USF equipadas | USF | P | - | 129 | - | 4,658,190.01 |
| | | | P (a) | - | 129 | - | 4,658,190.01 |
| | | | A | - | - | - | - |
| 1.04 | Hospitales equipados | Hospitales | P | - | 4 | - | 4,748,187 |
| | | | P (a) | - | 4 | - | 4,748,187 |
| | | | A | - | - | - | - |
| 1.05 | Centro de Simulación Clínica del MSPBS construido y equipado | Centro | P | - | 1 | 81,999.99 | 1,563,999.99 |
| | | | P (a) | - | 1 | - | 1,563,999.32 |
| | | | A | - | - | - | - |
| 1.06 | Recursos Humanos capacitados y entrenados en vigilancia de la mortalidad materna, fetal y neonatal | Profesionales | P | 766 | 1,531 | 169,668.36 | 458,100 |
| | | | P (a) | - | 1,531 | - | 458,100 |
| | | | A | - | - | - | - |

Component Nbr. 2 Apoyo a la mejora de la gestión, al uso de tecnologías y al impulso de la innovación en salud

| | | | | PHYSICAL PROGRESS | | FINANCIAL PROGRESS | |
|------|---|-------------------------|-------|-------------------|-------|--------------------|--------------|
| | Output | Unit of Measure | | 2021 | EOP 0 | 2021 | EOP 0 |
| 2.01 | Plan de implementación de las redes y micro redes elaborado | Plan diseñado | P | 1 | 1 | 64,400 | 262,799.97 |
| | | | P (a) | - | 1 | - | 262,799.97 |
| | | | A | - | - | - | - |
| 2.02 | Redes y Micro redes en las cuatro regiones implementadas | Redes y Microrredes | P | - | 4 | 262,499.99 | 1,227,600.02 |
| | | | P (a) | - | 4 | - | 1,227,600.02 |
| | | | A | - | - | - | - |
| 2.03 | Nuevos instrumentos de gestión regional implementados | Instrumentos de gestión | P | - | 1 | 36,250 | 100,000 |
| | | | P (a) | - | 1 | - | 100,000.77 |
| | | | A | - | - | - | - |
| 2.04 | Estudios de carrera sanitaria implementados | Estudios | P | 2 | 3 | 263,200.22 | 696,200.03 |
| | | | P (a) | - | 3 | - | 696,200.03 |
| | | | A | - | - | - | - |
| 2.05 | HIS implementado | Sistema implementado | P | - | 135 | 292,454.56 | 431,900.01 |
| | | | P (a) | - | 135 | - | 431,900.01 |
| | | | A | - | - | - | - |
| 2.06 | Normas y protocolos nacionales para la salud digital, aprobados | Normas aprobadas | P | 1 | 4 | 10,000 | 20,000 |
| | | | P (a) | - | 4 | - | 20,000 |
| | | | A | - | - | - | - |
| 2.07 | Política Nacional de Calidad en Salud, implementada | Plan | P | - | 1 | 489,937.51 | 1,645,000.03 |
| | | | P (a) | - | 1 | - | 1,645,000.03 |
| | | | A | - | - | - | - |
| 2.08 | Campaña de comunicación ejecutada | campaña | P | 1 | 1 | 80,454.54 | 100,000 |
| | | | P (a) | - | 1 | - | 100,000 |
| | | | A | - | - | - | - |
| 2.09 | Encuesta sobre salud sexual y reproductiva implementada | Encuesta | P | - | 2 | 760,227.27 | 1,276,000 |
| | | | P (a) | - | 2 | - | 1,276,000 |
| | | | A | - | - | - | - |

| Other Cost | | | | |
|------------|------------------------------------|-------|--------------|--------------|
| | Unidad de Gestión del Programa | P | 357,095.47 | 1,710,000.03 |
| | | P (a) | 0 | 1,709,999.93 |
| | | A | 0 | 0 |
| | Evaluación Intermedia y de Impacto | P | 92,000 | 249,999.98 |
| | | P (a) | 0 | 249,999.98 |
| | | A | 0 | 0 |
| | Auditoria externa | P | 30,000 | 180,000 |
| | | P (a) | 0 | 180,000 |
| | | A | 0 | 0 |
| Total Cost | | | | |
| | Total Cost | P | 3,287,818.34 | 45,000,000 |
| | | P (a) | 0 | 45,000,000 |
| | | A | 0 | 0 |

No information available for this section

IMPLEMENTATION STATUS AND LEARNING

| Lesson Learned - Categories |
|---|
| Others - Dimensions Related to Public Processes/ Actors |